<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">METFORMIN <img border="0" src="../images/pr.gif"/></span><br/>(met-for'min)<br/><span class="topboxtradename">Fortamet, </span><span class="topboxtradename">Glucophage, </span><span class="topboxtradename">Glucophage XR, </span><span class="topboxtradename">Glumetza, Riomet<br/></span><b>Classifications:</b> <span class="classification">hormones &amp; synthetic substitutes</span>; <span class="classification">antidiabetic agent</span>; <span class="classification">biguanides</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg, 850 mg, 1000 mg tablets; 500 mg, 750 mg, 1000 mg sustained-release tablets; 100 mg/mL oral solution</p>
<h1><a name="action">Actions</a></h1>
<p>Biguanide oral hypoglycemic agent. Unlike sulfonylureas, biguanides do not stimulate the release of insulin from the beta
         cells of the pancreas. Mechanism of action is thought to be due to both increasing the binding of insulin to its receptor
         and potentiating insulin action.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Improves tissue sensitivity to insulin, increases glucose transport into skeletal muscles and fat, and suppresses gluconeogenesis
         and hepatic production of glucose, thus lowering blood glucose levels.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of type 2 diabetes mellitus in patients not controlled with diet alone. May be used with an oral sulfonylurea.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to metformin; hepatic or cardiopulmonary insufficiency; alcoholism; concurrent infection; acute MI, cardiogenic
         shock; diabetic ketoacidosis; hypoxemia, lactic acidosis; radiographic contrast administration; renal disease, renal failure,
         renal impairment; sepsis; surgery; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Previous hypersensitivity to phenformin or buformin; anemia; coma; dehydration, diarrhea; older adults; ethanol intoxication;
         fever; gastroparesis, GI obstruction; heart failure; hyperthyroidism, pituitary insufficiency; polycystic ovary syndrome;
         trauma, emesis; pregnancy (category B).
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Type 2 Diabetes Mellitus</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 500 mg q.d. to t.i.d. or 850 mg q.d. to b.i.d. with meals, may increase by 500850 mg/d every 13 wk
               (max: 2550 mg/d); or start with 500 mg sustained-release with p.m. meal, may increase by 500 mg/d at p.m. meal qwk (max: 2000
               mg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Ensure that extend-release tablets are not crushed or chewed. They must be swallowed whole.</li>
<li>Use a calibrated oral syringe or container to measure the oral solution for accurate dosing.</li>
<li>Give with or shortly after main meals.</li>
<li>Withhold metformin 48 h before and 48 h after receiving IV contrast dye.</li>
<li>Make dose increment, if needed, at 2- to 3-wk intervals.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, dizziness, agitation, fatigue. <span class="typehead"> Metabolic:</span> Lactic acidosis. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, abdominal pain, bitter or metallic taste, diarrhea, bloatedness, anorexia;</span> malabsorption of amino acids, vitamin B<sub>12</sub>, and folic acid possible. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Captopril,</b>
<b>furosemide,</b>
<b>nifedipine</b> may increase risk of hypoglycemia. <b>Cimetidine</b> reduces clearance of metformin. Concomitant therapy with <span class="classification">azole antifungal agents</span>
<b>(fluconazole,</b>
<b>ketoconazole,</b>
<b>itraconazole)</b> and <span class="classification">oral hypoglycemic drugs</span> has been reported in severe hypoglycemia. <span class="classification">iodinated radiocontrast dyes</span> can cause lactic acidosis and acute kidney failure. <b>Amiloride,</b>
<b>cimetidine digoxin,</b>
<b>dofetilide,</b>
<b>midodrine,</b>
<b>morphine,</b>
<b>procainamide,</b>
<b>quinidine,</b>
<b>quinine,</b>
<b>ranitidine,</b>
<b>triamterene,</b>
<b>trimethoprim,</b>
<b>or vancomycin</b> may decrease metformin elimination by competing for common renal tubular transport systems. <b>Acarbose</b> may decrease metformin levels. <b>Iodinated contrast dyes</b> may cause lactic acidosis or acute kidney failure. <span class="typehead">Herbal:</span>
<b>Garlic,</b>
<b>ginseng</b> may increase hypoglycemic effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 5060% of dose reaches systemic circulation. <span class="typehead">Peak:</span> 13 h. <span class="typehead">Distribution:</span> Not bound to plasma proteins. <span class="typehead">Metabolism:</span> Not metabolized. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 6.217.6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Obtain baseline and periodic kidney and liver function tests; drug contraindicated in the presence of renal or
            hepatic insufficiency. Monitor blood glucose and HbA<sub>1C</sub>, and lipid profile periodically.
         </li>
<li>Monitor known or suspected alcoholics carefully for decreased liver function.</li>
<li>Monitor cardiopulmonary status throughout course of therapy; cardiopulmonary insufficiency may predispose to lactic acidosis.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware that hypoglycemia is not a risk when drug is taken in recommended therapeutic doses unless combined with other drugs
            which lower blood glucose.
         </li>
<li>Report to physician immediately S&amp;S of infection, which increase the risk of lactic acidosis (e.g., abdominal pains, nausea,
            and vomiting, anorexia).
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>